Episode notes
You started semaglutide or tirzepatide and something changed at night — vivid dreams, waking at three with your heart going. You checked the leaflet and sleep isn't listed.
The strongest data is genuinely good news: tirzepatide cut apnea events by about twenty-five to twenty-nine an hour in the SURMOUNT-OSA trials, and became the first drug ever approved specifically for obstructive sleep apnea. The dreams-and-insomnia story is much weaker, and we're careful about saying so.
SOURCES:
Malhotra et al., SURMOUNT-OSA, New England Journal of Medicine, 2024
FDA approval of tirzepatide for OSA, December 2024
Written and fact-checked by Brent Burgess. Narration uses a synthetic voice model of his own voice.
This episode is general education and is not medical advice. Sleep problems can have serious underlying causes — talk to your doctor before changing medication, supplements, or treatment.